DBS Keeps Their Buy Rating on UMS Holdings (UMSSF)
Elevate Your Investing Strategy:
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
According to TipRanks, Lee Keng is a 4-star analyst with an average return of 6.8% and a 48.42% success rate. Lee Keng covers the Technology sector, focusing on stocks such as Frencken Group Limited, iFAST Corporation Ltd, and Aztech Global Ltd..
In addition to DBS, UMS Holdings also received a Buy from UOB Kay Hian's John Cheong in a report issued on July 16. However, yesterday, TR | OpenAI – 4o reiterated a Hold rating on UMS Holdings (Other OTC: UMSSF).
Based on UMS Holdings' latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $67.23 million and a net profit of $11.1 million. In comparison, last year the company earned a revenue of $73.52 million and had a net profit of $15.67 million
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Miami Herald
an hour ago
- Miami Herald
Adapti, Inc. (OTC: ADTI) Announces Contract Extension of MLB Pitcher Seth Lugo Facilitated by Ballengee Group
LAS VEGAS, NV / ACCESS Newswire / August 1, 2025 / Adapti, Inc. (OTC:ADTI) announced today that its newly acquired baseball agency, The Ballengee Group, successfully facilitated a multi-year contract extension for Kansas City Royals starting pitcher Seth Lugo. Lugo, who has been one of the American League's most consistent pitchers in 2025, signed a two-year extension worth $40 million, with a third-year player option of up to $20 million. The contract extension marks another significant milestone for Ballengee Group, reinforcing the agency's long-standing reputation for advocating top-tier talent and securing strong high value deals for its clients. "Seth Lugo's extension with Kansas City is a testament to the leadership and experience of the Ballengee team, and to Seth's agent, Scott Barber," said Adam Nicosia, CEO of Adapti. "Ballengee's boots-on-ground approach and deep relationships across the league consistently delivers results that reflect the best interest of its athletes." The Ballengee Group, acquired by Adapti in July 2025, is a full-service sports agency representing professional baseball athletes. The agency is committed to client service, expert contract negotiations, and has a track record of advocating for high-character, high-performance players. About Adapti, Inc. (OTC: ADTI) Adapti, Inc. leverages advanced AI technology to match products and brands with optimal influencers, using proprietary data analytics to drive superior marketing results. Adapti aims to build a global platform where data is an asset, efficiently paired with high-impact influencers. In July 2025, Adapti acquired the Ballengee Group, a full-service sports agency representing Major League Baseball athletes. The Ballengee Group assists its clients with contract negotiations, marketing deals, public relations, and strategic partnerships. The Ballengee Group has guided world champions and global icons throughout their careers. Adapti plans to roll out a suite of integrated services that blend traditional contract negotiation and endorsement deals with dynamic social media campaigns, which we anticipate will be powered by AdaptAI's proprietary "data fingerprint" technology that the company is developing. This technology will utilize Large Language Models to quickly optimize and adapt to changes in the ever-evolving marketing landscape. This holistic approach is being designed to maximize engagement, drive higher ROI for brand partners, and ensure athletes capture every opportunity to grow their platforms. For more information, please visit our website: The information contained on our website is not incorporated by reference into this press release, and we disclaim any liability for such information. Forward-Looking Statements This communication contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Adapti, Inc. generally identify forward-looking statements by terminology such as "may," "should," "expects," "plans," "anticipates," "could," "intends," "target," "projects," "contemplates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other similar words. These statements are only predictions. Adapti based these forward-looking statements largely on their then-current expectations and projections about future events and financial trends as well as the beliefs and assumptions of management. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond Adapti's control. Adapti's actual results (including those of Ballengee post-acquisition) could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to: (i) the ability to integrate the business operations of Ballengee with that of Adapti, (ii) the ability of Adapti to timely make the necessary filings with the SEC related to the acquisition of Ballengee, and (iii) those risks detailed in Adapti's reports filed with the SEC, as well as other documents that may be filed by Adapti from time to time with the SEC. Accordingly, you should not rely upon forward-looking statements as predictions of future events. Additional risks and uncertainties can be found in the Company's recent annual and quarterly reports, filed with the SEC or other filings that are filed with the SEC thereafter. Adapti cannot assure you that the events and circumstances reflected in the forward-looking statements will be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. The forward-looking statements made in this communication relate only to events as of the date on which the statements are made. Except as required by applicable law or regulation, Adapti undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events. Investors Contact: Phone: 214-301-3745Email: investorrelations@ SOURCE: Adapti, Inc.
Yahoo
5 hours ago
- Yahoo
Closure Systems International introduces new child-resistant closure platform
Closure Systems International (CSI) has launched a new child-resistant closure (CRC) platform, named Defender-Lok. The company noted that Defender-Lok has been specifically tailored for use in the over-the-counter (OTC) and nutraceutical sectors, focusing on safety, efficiency, and sustainability. Defender-Lok is designed to fit into existing capping and filling operations, aiming to reduce downtime, feeder jams, and sealing issues. The new closure system is expected to enhance production efficiency, streamline validation processes, and maintain consistent output. It has received certification for being child-resistant and accommodating for older users, addressing safety concerns for both producers and consumers. Notable characteristics of Defender-Lok include its certified CRC design, sustainable construction, high-speed capabilities, tamper-evident features, and compatibility with various liner types. The closures are offered in adaptable formats to meet different market requirements. In light of increasing extended producer responsibility regulations and specific US state mandates such as California's Senate Bill 54 (SB-54), the focus on sustainability has intensified. Defender-Lok is said to have been designed to minimise material use, thereby decreasing resin consumption, shipping weight, and overall environmental impact. CSI has reported that certain stock-keeping units already meet or exceed the 2027 SB-54 targets, and all closures in this line can be manufactured using CSI's PolyCycle post-consumer recycled resin, which is fully recyclable. CSI Pharmaceutical Packaging global commercial innovation and technical development director Chuck Newswanger said: 'In the OTC and nutraceutical market, child-resistant closures demonstrate a brand's commitment to consumer safety and regulatory compliance. 'A well-engineered design meets the expectations of today's health-conscious shoppers, ensures compliance, and integrates seamlessly with high-speed filling and capping lines.' "Closure Systems International introduces new child-resistant closure platform" was originally created and published by Packaging Gateway, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Hamilton Spectator
7 hours ago
- Hamilton Spectator
Aptose Selects Ernst & Young Global Limited as its New Independent Auditor and Calls Reconvened Meeting of its Shareholders
SAN DIEGO and TORONTO, Aug. 01, 2025 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. ('Aptose' or the 'Company') (TSX: APS; OTC: APTOF; OTCQB: APTOF), a clinical-stage precision oncology company developing a tuspetinib (TUS) based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), announced today that the Company's Board of Directors (the 'Board') has unanimously approved the selection of Ernst & Young LLP ('EY') as the Company's independent registered public accounting firm to serve as the Company's independent auditor. The Company had previously adjourned their Annual and Special Meeting of shareholders held on May 27, 2025 (the 'Original Meeting'), for the purposes of completing its search for a successor independent auditor. EY is a top-ranked global accounting firm that offers a complete spectrum of tax, assurance, and advisory services; they have been selected due to their expertise, capabilities, fit, and understanding of the Company's industry and business. The Company will reconvene its Annual General and Special Meeting of shareholders (the 'Reconvened Meeting') on August 22, 2025 at 10:00 a.m. (Eastern Time) to vote on the appointment of EY and the authorization of the Board to fix EY's remuneration. All interested parties are invited to attend the Reconvened Meeting by using the live webcast link here: . Only registered shareholders and duly appointed proxyholders as of the record date on April 22, 2025, will be entitled to vote and ask questions at the Reconvened Meeting. Unless properly revoked, proxies previously completed, signed, dated and returned in respect of the Original Meeting will be effective at the Reconvened Meeting and shareholders do not need to vote again. New forms of proxies are not being distributed by the Company. Registered shareholders of record at the close of business on April 22, 2025, who have not previously deposited a form of proxy may deposit a properly executed form of proxy no later than 48 hours, excluding weekends and holidays, before the Reconvened Meeting, or any adjournments or postponements thereof, with Computershare Investor Services Inc. (i) via the internet at: ; (ii) by phone at: 1-866-732-VOTE (8683); or (iii) by mail to Computershare Investor Services Inc., 320 Bay Street, 14th Floor, Toronto, Ontario, M5H 4A6. Copies of the proxy statement and form of proxy have been filed on SEDAR+ and are available electronically at . Beneficial shareholders who wish to vote must follow the procedures and instructions received from their brokers or other intermediaries, and contact their brokers or other intermediaries if they need assistance. About Aptose Aptose Biosciences is a clinical-stage biotechnology company committed to developing precision medicines addressing unmet medical needs in oncology, with an initial focus on hematology. The Company's lead clinical-stage, oral kinase inhibitor tuspetinib (TUS) has demonstrated activity as a monotherapy and in combination therapy in patients with relapsed or refractory acute myeloid leukemia (AML) and is being developed as a frontline triplet therapy in newly diagnosed AML. For more information, please visit . Forward Looking Statements This press release may contain forward-looking statements within the meaning of Canadian and U.S. securities laws, including statements relating but not limited to, the appointment of a new independent auditor of the Company, the date and time of the Reconvened Meeting, the development of tuspetinib, and statements relating to the Company's plans, objectives, expectations and intentions and other statements including words such as 'continue', 'expect', 'intend', 'will', 'should', 'would', 'may', and other similar expressions. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by us are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance or achievements described in this press release. Such factors could include, among others: our ability to appoint a new independent auditor, our ability to hold the Reconvened Meeting and other risks detailed from time-to-time in our ongoing quarterly filings, annual information forms, annual reports and annual filings with Canadian securities regulators. Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled 'Risk Factors' in our filings with Canadian securities regulators underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by law. We cannot assure you that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Investors are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein. For further information, please contact: Aptose Biosciences Inc. Susan Pietropaolo Corporate Communications & Investor Relations 201-923-2049 spietropaolo@
